Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

More Efficient Generation of β-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells

Naoya Uchida, Fujita Atsushi, Haro-Mora J Juan, Thomas Winkler, MD, John F Tisdale, MD

Blood (2015) 126 (23): 1150.

https://doi.org/10.1182/blood.V126.23.1150.1150

Published: 2015

Journal Articles

An Optimized, Large Scale Generation and Validation of Aspergillus-Specific T Lymphocytes for the Management of Invasive Aspergillosis in Immunocompromised Patients

Anastasia Papadopoulou, PhD, Panayotis Kaloyannidis, MD, Maria Alvanou, Joanne Kalogeropoulou, Achilles Anagnostopoulos, Evangelia Yannaki, MD

Blood (2015) 126 (23): 4293.

https://doi.org/10.1182/blood.V126.23.4293.4293

Published: 2015

Journal Articles

Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients,

Martina Kleber, Kerstin Höck, Gabriele Ihorst, Bernd Koch, Ralph Waesch, MD, Monika Engelhardt, MD

Blood (2011) 118 (21): 3929.

https://doi.org/10.1182/blood.V118.21.3929.3929

Published: 2011

Journal Articles

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

Alison J. Moskowitz, Joachim Yahalom, Tarun Kewalramani, Jocelyn C. Maragulia, Jill M. Vanak, Andrew D. Zelenetz, Craig H. Moskowitz

Blood (2010) 116 (23): 4934–4937.

https://doi.org/10.1182/blood-2010-05-282756

Published: 2010

Journal Articles

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Andrew J. Lurie, BGS, Mark V. Mai, Martin S. Tallman, MD, June McCoy, MD JD MPH, Charles L. Bennett, MD PhD MPP

Blood (2006) 108 (11): 3318.

https://doi.org/10.1182/blood.V108.11.3318.3318

Published: 2006

Journal Articles

Individualized risks of first adverse events in patients with Fanconi anemia

Philip S. Rosenberg, Yi Huang, Blanche P. Alter

Blood (2004) 104 (2): 350–355.

https://doi.org/10.1182/blood-2004-01-0083

Published: 2004

Journal Articles

Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors

Blood (2004) 103 (2): 435–441.

https://doi.org/10.1182/blood-2003-07-2236

Published: 2004

NARROW

More Efficient Generation of β-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells

An Optimized, Large Scale Generation and Validation of Aspergillus-Specific T Lymphocytes for the Management of Invasive Aspergillosis in Immunocompromised Patients

Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients,

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Individualized risks of first adverse events in patients with Fanconi anemia

Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors

Email alerts

ASH Publications

American Society of Hematology

More Efficient Generation of β-Globin-Expressing Erythroid Cells Using Stromal Cell-Derived Induced Pluripotent Stem Cells

An Optimized, Large Scale Generation and Validation of Aspergillus-Specific T Lymphocytes for the Management of Invasive Aspergillosis in Immunocompromised Patients

Risks for Different Neoplasms (DNs) in Multiple Myeloma (MM) Patients May Involve Specific Host-, Myeloma- and Treatment-Related Susceptibilities: Registry Data of 681 Consecutive MM Patients,

Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma

2006 RADAR Report Card on Conversion Rates from Accelerated FDA Approval to Regular FDA Approval for Drugs Used To Treat Hematologic Malignancies: Policy Changes Continue To Be Needed.

Individualized risks of first adverse events in patients with Fanconi anemia

Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only